Factors modulating food intake and energy expenditure prior to liver transplantation
DOI:
https://doi.org/10.23938/1137-6627/2016000100012Keywords:
cirrosis hepática, leptina, ghrelina, glucagón, IGF-IAbstract
ABSTRACT
Background. There is a high prevalence of nutritional disorders in patients with liver cirrhosis (LC). This study was designed to assess the relationships between liver function, IFG-I/IGFBP-3, nutritional status, leptin, ghrelin and glucagon in 21 patients waiting for liver transplantation (LT).
Methods. We studied 21 men aged 56+2.1 years who were on the LT list. They were classified according to Child-Pugh (CP) score from low to high liver dysfunction in CPA (n=4), CPB (n=11) and CPC (n=6). Body mass index (BMI) was calculated and body fat (%) was measured by air-displacement plethysmography. Resting energy expenditure (REE) and its variation over Harris-Benedict values (GER%) was assessed by indirect calorimetry. Fasting serum samples were taken to measure albumin, glucose, insulin, HbA1c, leptin, total ghrelin, glucagon, IGF-I and IGFBP3.
Results. There were no differences in fat % and leptin values in the three groups according to CP classification. The CPC group showed higher ghrelin values than CPA and CPB (p<0.05). All groups displayed high glucagon levels and GER% values superior to 100%. Positive correlations were found between glucagon and GER% (r=0.56; p<0.01) and between glucagon and ghrelin values (r=0.66; p<0.01). IGF-I and IGFBP3 were low in all groups and showed a positive correlation with plasma albumin (r=0.52; p<0.05 and r=0.45; p<0.05 respectively).
Conclusions. These results show an increase in ghrelin plasma values in patients with severe liver dysfunction. Hyperglucagonemia was correlated with GER%, supporting a role of glucagon in the hypermetabolic state associated to LC, raising the possibility of becoming a therapeutic target. The measurement of IGF-I/IGFBP3 represents a good marker of liver function in patients with LC.
Key words. Liver cirrhosis. Leptin. Ghrelin. Glucagon. IGF-I
Downloads
References
1. MAHARSHI S, SHARMA BC, SRIVASTAVA S. Malnutrition in cirrhosis increases morbidity and mortality. J Gastroenterol Hepatol 2015; 30: 1507-1513 doi: 10.1111/jgh.12999.
https://doi.org/10.1111/jgh.12999
2. FAROOQI IS, O'RAHILLY S. LEPTIN: a pivotal regulator of human energy homeostasis. Am J Clin Nutr 2009; 89: 980S-984S.
https://doi.org/10.3945/ajcn.2008.26788C
3. MULLER TD, NOGUEIRAS R, ANDERMANN ML, ANDREWS ZB, ANKER SD, ARGENTE J et al. Ghrelin. Mol Metab 2015; 4: 437-460.
https://doi.org/10.1016/j.molmet.2015.03.005
4. OSTLUND JR RE, WANG JW, KLEIN S, GINGERICH R. Relation between plasma leptin concentration and body fat, gender, diet, age and metabolic covariates. J Clin Endocrinol Metab 1996; 81: 173-179.
https://doi.org/10.1210/jcem.81.11.8923837
5. CRUJEIRAS AB, DÍAZ-LAGARES A, ABETE I, GOYENECHEA E, AMIL M, MARTÍNEZ JA et al. Pre-treatment circulating leptin/ghrelin ratio as a non-invasive marker to identify patients likely to regain the lost weight after an energy restriction treatment. J Endocrinol Invest 2014; 37: 119-126.
https://doi.org/10.1007/s40618-013-0004-2
6. DORNELLES CT, GOLDANI HA, WILASCO MI, MAURER RL, KIELING CO, POROWSKI M et al. Ghrelin, leptin and insulin in cirrhotic children and adolescents: relationship with cirrhosis severity and nutritional status. Regul Pept 2013; 180: 26-32.
https://doi.org/10.1016/j.regpep.2012.10.004
7. CAMPBELL JE, DRUCKER DJ. Islet cells and glucagon-critical regulators of energy homeostasis. Nat Rev Endocrinol 2015; 11: 3239-3338.
https://doi.org/10.1038/nrendo.2015.51
8. CASTRO GR, COELHO JC, PAROLIN MB, MATIAS JE, DE FREITAS AC. Insulin-like growth factor I correlates with MELD and returns to normal level after liver transplantation. Ann Transplant 2013; 18: 57-62.
https://doi.org/10.12659/AOT.883819
9. WELLS JCK, FULLER NJ. Precision of measurement and body size in whole-body air-displacement plethysmography. Int J Obes 2001; 25: 1161-1167.
https://doi.org/10.1038/sj.ijo.0801634
10. BOOI AN, MENENDEZ J, NORTON HJ, ANDERSON WE, ELLIS AC. Validation of a screening tool to identify undernutrition in ambulatory patients with liver cirrhosis. Nutr Clin Pract 2015; 30: 683-689 doi 10.1177 pii: 0884533615587537.
https://doi.org/10.1177/0884533615587537
11. BONEFELD K, MØLLER S. Insulin-like growth factor-I and the liver. Liver Int 2011; 31: 911-919.
https://doi.org/10.1111/j.1478-3231.2010.02428.x
12. ASSY N, PRUZANSKY Y, GAITINI D, SHEN ORR Z, HOCHBERG Z, BARUCH Y et al. Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol 2008; 49: 34-42.
https://doi.org/10.1016/j.jhep.2008.02.013
13. BOLUBKAS FF, BOLUBKAS C, HOROZ M, GUMUS M, ERDOGAN M, ZEYREK F et al. Child-Pugh classification dependent alterations in serum leptin levels among cirrhotic patients: a case controlled study. BMC Gastroenterology 2004; 4: 23.
https://doi.org/10.1186/1471-230X-4-23
14. LIU YL, YAKAR S, OTERO-CORCHON V, LOW MJ, LIU JL. Ghrelin gene expression is age-dependent and influenced by gender and the level of circulating IGF-1. Mol Cell Endocrinol 2002; 189: 97-103.
https://doi.org/10.1016/S0303-7207(01)00742-0
15. EL-SHEHABY AM, OBAIA EM, ALWAKIL SS, HIEKAL AA. Total and acylated ghrelin in liver cirrosis: correlation with clinical and nutritional status. Scand J Clin Lab Invest 2010; 70: 252-258.
https://doi.org/10.3109/00365511003763349
16. TACKE F, BRABANT G, KRUCK E, HORN R, SCHÖFFSKI P, HECKER H et al. Ghrelin in chronic liver disease. J Hepatol 2003; 38: 447-454.
https://doi.org/10.1016/S0168-8278(02)00438-5
17. MARCHESINI G, BIANCHI G, LUCIDI P, VILLANOVA N, ZOLI M, DE FEO P et al. Plasma ghrelin concentrations, food intake and anorexia in liver failure. J Clin Endocrinol Metab 2004; 89: 2136-2141.
https://doi.org/10.1210/jc.2003-031771
18. KASEB AO, MORRIS JS, HASSAN MM, SIDDIQUI AM, LIN E, XIAO L et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011; 29: 3892-3899.
https://doi.org/10.1200/JCO.2011.36.0636
19. CONCHILLO M, PRIETO J, QUIROGA J. Insulin-like growth factor I and liver cirrhosis. Rev Esp Enferm Dig 2007; 99: 156-164.
https://doi.org/10.4321/S1130-01082007000300007
20. SU AP, CAO SS, LE TIAN B, DA ZHANG Z, HU WM, ZHANG Y et al. Effect of transjugular intrahepatic portosystemic shunt on glycometabolism in cirrhosis patients. Clin Res Hepatol Gastroenterol 2012; 36: 53-59.
https://doi.org/10.1016/j.clinre.2011.09.011
21. HABEGGER KM, HEPPNER KM, GEARY N, BARTNESS TJ, DIMARCHI R, TSCHÖP MH el al. The metabolic actions of glucagon revisited. Nat Rev Endocrinol 2010; 6: 689-697.
https://doi.org/10.1038/nrendo.2010.187
22. AHREN B. Glucagon-early breakthroughs and recent discoveries. Peptides 2015; 67: 74-81.
https://doi.org/10.1016/j.peptides.2015.03.011
23. ARAFAT MA, OTTO B, ROCHLITZ H, TSCHÖP M, BÄHR V, MÖHLIG M et al. Glucagon inhibits ghrelin secretion in humans. Eur J Endocrinol 2005; 153: 397-402.
https://doi.org/10.1530/eje.1.01981
24. LUND A, BAGGER JI, CHRISTENSEN M, KNOP FK, VILSBOLL T. Glucagon and type 2 diabetes: the return of the alpha cell. Curr Diab Rep 2014; 14: 555 doi: 10.1007/s11892-014-0555-4
https://doi.org/10.1007/s11892-014-0555-4
25. HERUC GA, HOROWITZ M, DEACON CF, FEINLE-BISSET C, RAYNER CK, LUSCOMBE-MARSH N et al. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males. Am J Physiol Endocrinol Metab 2014; 307: E830-E837.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
